News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

SAGE Therapeutics Announces Closing Of Initial Public Offering



7/23/2014 12:16:23 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass.--(BUSINESS WIRE)--SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced the closing of its initial public offering of 5,750,000 shares of its common stock at a public offering price of $18.00 per share, before underwriting discounts, which includes the exercise in full by the underwriters of their option to purchase up to 750,000 additional shares of common stock. All of the common stock was offered by SAGE. The company's common stock is listed on The NASDAQ Global Market under the symbol "SAGE."

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES